Temozolomide for corticotroph pituitary adenomas refractory to standard therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Temozolomide for corticotroph pituitary adenomas refractory to standard therapy

Published:2010-10-24 Issue:1 Volume:14 Page:80-91
ISSN:1386-341X
Container-title:Pituitary
language:en
Short-container-title:Pituitary

Author:

Dillard Troy H.,Gultekin S. Humayun,Delashaw Johnny B.,Yedinak Chris G.,Neuwelt Edward A.,Fleseriu Maria

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1007/s11102-010-0264-1.pdf

Reference54 articles.

1. Assié G, Bahurel H, Coste J, Silvera S, Kujas M, Dugué M-A, Karray F, Dousset B, Bertherat J, Legmann P, Bertagna X (2007) Corticotroph tumor progression after adrenalectomy in Cushing’s Disease: a reappraisal of Nelson’s Syndrome. J Clin Endocrinol Metab 92:172–179

2. Blevins LS, Sanai N, Kunwar S, Devin JK (2009) An approach to the management of patients with residual Cushing’s disease. J Neuro-Oncol 94:313–319

3. Bobola MS, Kolstoe DD, Blank A, Silber JR (2010) Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression. Mol Cancer Ther 9:1208–1218

4. Bobola MS, Silber JR, Ellenbogen RG, Geyer JR, Blank A, Goff RD (2005) O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines. Clin Cancer Res 11:2747–2755

5. Bode H, Seiz M, Lammert A, Brockmann MA, Back W, Hammes HP, Thome C (2010) SOM230 (Pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Exp Clin Endocrinol Diabetes, 2010 May 21 [Epub ahead of print]

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bone mineral density in patients with Cushing’s syndrome;Marmara Medical Journal;2024-05-31

2. Pituitary adenoma. Clinical case;Medical alphabet;2024-04-27

3. Current and Emerging Pharmacological Therapies for Cushing's Disease;Current Pharmaceutical Design;2024-03

4. Recurrent Cushing Disease: An Extensive Review on Pros and Cons of Different Therapeutic Approaches;World Neurosurgery;2023-04

5. Knowing when to discontinue Temozolomide therapy in responding aggressive pituitary tumors and carcinomas: a systematic review and Padua (Italy) case series;Expert Review of Endocrinology & Metabolism;2023-03-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3